Immunotoxin therapy for hematologic malignancies: Where are we heading?

Drug Discovery Today

Volumn 21, Issue 2, 2016, Pages 325-332

  Madhumathi, Jayaprakasam ^a   Devilakshmi, Sithambaram ^a   Sridevi, Surapally ^a   Verma, Rama S ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD33 ANTIGEN; CD64 ANTIGEN; CD7 ANTIGEN; CD74 ANTIGEN; FC RECEPTOR; FC RECEPTOR LIKE 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IMMUNOTOXIN; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3 RECEPTOR; JL 1 PROTEIN; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; STEM CELL FACTOR RECEPTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG; LIGAND;

CYTOTOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; ANIMAL; HEMATOLOGIC NEOPLASMS;

ANIMALS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTOXINS; LIGANDS;

EID: 84930813662     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.05.002     Document Type: Review

References (59)

1. S. Potala Targeted therapy of cancer using diphtheria toxin-derived immunotoxins Drug Discov. Today 17-18 2008 807 815
2. S. Choudhary, and et al. Therapeutic potential of anticancer immunotoxins Drug Discov. Today 11-12 2011 495 503
3. J. Madhumathi, and R.S. Verma Therapeutic targets and recent advances in protein immunotoxins Curr. Opin. Microbiol. 15 2012 300 309
4. R.J. Kreitman Immunotoxins for targeted cancer therapy AAPS J. 8 2006 E532 E551
5. M. Schwemmlein, and et al. A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells Leukemia 21 2007 1405 1412
6. L.K. Tsai, and et al. A comparison of the anti-tumor effects of a chimeric versus murine anti-CD19 immunotoxins on human B cell lymphoma and Pre-B acute lymphoblastic leukemia cell lines Toxins (Basel) 3 2011 409 419
7. L. Herrera, and et al. A Phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia J. Pediatr. Hematol. Oncol. 31 2009 936 941
8. J. Schindler, and et al. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia Br. J. Haematol. 54 2011 471 476
9. S.K. Barta, and et al. Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia Leuk. Lymphoma 10 2012 1999 2003
10. D.J. Flavell, and et al. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma Br. J. Haematol. 134 2006 157 170
11. K. Tobinai Rituximab and other emerging monoclonal antibody therapies for lymphoma Int. J. Clin. Oncol. 8 2003 212 223
12. L. Polito, and et al. The conjugate rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with fludarabine Leukemia 18 2004 1215 1222
13. J. Kato, and et al. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia Leuk. Res. 37 2013 83 88
14. R. Lechleider, and I. Pastan Advances in the development of anti-CD22 immunotoxins containing pseudomonas exotoxin for treatment of hematologic malignancies J. Cancer Sci. Ther. 3 2011 3
15. R.J. Kreitman, and et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia J. Clin. Oncol. 27 2009 2983 2990
16. R.J. Kreitman, and et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies J. Clin. Oncol. 23 2005 6719 6729
17. A.S. Wayne, and et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial Clin. Cancer Res. 16 2010 1894 1903
18. A. Wayne, and et al. Complete remissions in 3 of 12 patients with pediatric acute lymphoblastic leukemia (ALL) during phase 1 testing of the anti-CD22 immunotoxin moxetumomab pasudotox Blood ASH Annu. Meet. Abstr. 116 2010 3246
19. R.J. Kreitman, and et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia J. Clin. Oncol. 30 2012 1822 1828
20. M. Onda An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes Proc. Natl. Acad. Sci. U. S. A. 105 2008 11311 11316
21. S. Bang, and et al. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity Clin. Cancer Res. 11 2005 1545 1550
22. S. Kawa, and et al. The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan MAbs 3 2011 479 486
23. M. Onda, and et al. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes Proc. Natl. Acad. Sci. U. S. A. 108 2011 5742 5747
24. W. Liu, and et al. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes Proc. Natl. Acad. Sci. U. S. A. 109 2012 11782 11787
25. R. Mazor, and et al. Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes Proc. Natl. Acad. Sci. U. S. A. 111 2014 8571 8576
26. T.K. Bera, and et al. An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies Leuk. Res. 38 2014 1224 1229
27. D.A. Vallera, and et al. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma Clin. Cancer Res. 11 2005 3879 3888
28. D.A. Vallera, and et al. Genetic alteration of a bispecific ligand directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy Leuk. Res. 33 2009 1233 1242
29. M.K. Tur, and et al. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA′ in a human acute myeloid leukemia xenograft tumor model Int. J. Cancer 129 2011 1277 1282
30. C. Hetzel, and et al. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells J. Immunother. 31 2008 370 376
31. B. Stahnke, and et al. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes Mol. Cancer Ther. 7 2008 2924 2932
32. M. Mathew, and R.S. Verma Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy Cancer Sci. 100 2009 1359 1365
33. A. Dean, and et al. Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies J. Clin. Oncol. 28 Suppl. 2010 15
34. G. Borthakur, and et al. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies Haematologica 98 2013 217 221
35. M. Schwemmlein, and et al. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells Br. J. Haematol. 133 2006 141 151
36. I. Pastan, and et al. Immunotoxin treatment of cancer Annu. Rev. Med. 58 2007 221 237
37. E. Bremer, and et al. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia Blood 107 2006 2863 2870
38. X. Du, and et al. FCRL1 on chronic lymphocytic leukemia, Hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins Blood 111 2008 338 343
39. D.A. Vallera, and et al. Molecular modification of a recombinant, bivalent anti-human CD3 immunotoxin (Bic3) results in reduced in vivo toxicity in mice Leuk. Res. 29 2005 331 341
40. A.E. Frankel, and et al. Anti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma Curr. Drug Targets 10 2009 104 109
41. Y.K. Shin, and et al. Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications Cancer Immunol. Immunother. 52 2003 506 512
42. L. Polito, and et al. Immunotoxins and other conjugates containing saporin-s6 for cancer therapy Toxins 3 2011 697 720
43. D.J. FitzGerald, and et al. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates Cancer Res. 71 2011 6300 6309
44. R.J. Kreitman Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies BioDrugs 23 2009 1 13
45. S. Potala, and R.S. Verma Modified DT-IL2 fusion toxin targeting uniquely IL2Ralpha expressing leukemia cell lines - construction and characterization J. Biotechnol. 148 2010 147 155
46. T.A. Larson, and et al. Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia Ocul. Immunol. Inflamm. 20 2012 312 314
47. N. Ohno, and et al. Augmentation of the activity of an immunotoxin, anti-Tac(Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I Leuk. Lymphoma 4 2002 885 888
48. R. Singh, and et al. Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy Clin. Cancer Res. 18 2012 152 160
49. J.P. Perentesis, and et al. Granulocyte-macrophage colony-stimulating factor receptor-targeted therapy of chemotherapy- and radiation-resistant human myeloid leukemias Leuk. Lymphoma 25 1997 247 256
50. R.J. Kreitman, and I. Pastan Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells Blood 90 1997 252 259
51. C.N. Kim, and et al. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor and Ara-C exert synergistic toxicity against human AML HL-60 cells Leuk. Res. 23 1999 527 538
52. A. Antignani, and R.J. Youle A chimeric protein induces tumor cell apoptosis by delivering the human Bcl-2 family BH3-only protein Bad Biochemistry 44 2005 4074 4082
53. M. Mathew, and et al. GM-CSF-DFF40: a novel humanized immunotoxin induces apoptosis in acute myeloid leukemia cells Apoptosis 8 2013 882 895
54. D.A. Vallera, and et al. Retroviral immunotoxin gene therapy of leukemia in mice using leukemia-specific T cells transduced with an interleukin-3/Bax fusion protein gene Hum. Gene Ther. 14 2003 1787 1798
55. A. Frankel, and et al. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia Leuk. Lymphoma 49 2008 543 553
56. X. Du, and et al. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells J. Immunother. 30 2007 607 613
57. S. Potala, and R.S. Verma A novel fusion protein diphtheria toxin-stem cell factor (DT-SCF)-purification and characterization Appl. Biochem. Biotechnol. 162 2010 1258 1269
58. S. Baskar, and et al. Targeting malignant B cells with an immunotoxin against ROR1 MAbs 4 2012 349 361
59. D. Baatar, and et al. CCR4-expressing T cell tumors can be specifically controlled via delivery of toxins to chemokine receptors J. Immunol. 179 2007 1996 2004